Cargando…

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

OBJECTIVES: To analyse the impact of cefiderocol use on outcome in patients admitted to the ICU for severe COVID-19 and further diagnosed with carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. METHODS: Retrospective multicentre observational study was performed at four Italian hospital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pascale, Renato, Pasquini, Zeno, Bartoletti, Michele, Caiazzo, Luca, Fornaro, Giacomo, Bussini, Linda, Volpato, Francesca, Marchionni, Elisa, Rinaldi, Matteo, Trapani, Filippo, Temperoni, Chiara, Gaibani, Paolo, Ambretti, Simone, Barchiesi, Francesco, Viale, Pierluigi, Giannella, Maddalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599913/ https://www.ncbi.nlm.nih.gov/pubmed/34806011 http://dx.doi.org/10.1093/jacamr/dlab174

Ejemplares similares

Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study
por: Pascale, Renato, et al.
Publicado: (2021)

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
por: Gaibani, Paolo, et al.
Publicado: (2021)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study
por: Bartoletti, Michele, et al.
Publicado: (2021)

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii
por: Daisey, Gabrielle N, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
por: Gatti, Milo, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
por: Gaibani, Paolo, et al.
Publicado: (2022)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
por: Stracquadanio, Stefano, et al.
Publicado: (2022)

Klebsiella pneumoniae Bloodstream Infection: Epidemiology and Impact of Inappropriate Empirical Therapy
por: Girometti, Nicolò, et al.
Publicado: (2014)

Acinetobacter baumannii response to cefiderocol challenge in human urine
por: Nishimura, Brent, et al.
Publicado: (2022)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)
por: Bartoletti, Michele, et al.
Publicado: (2020)

Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545–1553
por: Bartoletti, Michele, et al.
Publicado: (2023)

Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae
por: Viale, Pierluigi, et al.
Publicado: (2015)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
por: He, Yukun, et al.
Publicado: (2022)

High Prevalence of Antibiotic Resistance among Opportunistic Pathogens Isolated from Patients with COVID-19 under Mechanical Ventilation: Results of a Single-Center Study
por: Temperoni, Chiara, et al.
Publicado: (2021)

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections
por: Giannella, Maddalena, et al.
Publicado: (2019)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing Klebsiella pneumoniae
por: Bovo, Federica, et al.
Publicado: (2023)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
por: Mezcord, Vyanka, et al.
Publicado: (2023)

2134. Impact of ADC ß-lactamase amino acid variation on cefiderocol (FDC) susceptibility in carbapenem-resistant Acinetobacter baumannii (CRAb) strains
por: Iovleva, Alina, et al.
Publicado: (2023)

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
por: Giannella, Maddalena, et al.
Publicado: (2023)

Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport
por: Le, Casin, et al.
Publicado: (2022)

The Iron Content of Human Serum Albumin Modulates the Susceptibility of Acinetobacter baumannii to Cefiderocol
por: Escalante, Jenny, et al.
Publicado: (2023)

Impact on Mortality of a Bundle for the Management of Enterococcal Bloodstream Infection
por: Bartoletti, Michele, et al.
Publicado: (2019)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19
por: Russo, A., et al.
Publicado: (2023)

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
por: Rando, Emanuele, et al.
Publicado: (2021)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

Virulence role of the outer membrane protein CarO in carbapenem-resistant Acinetobacter baumannii
por: Labrador-Herrera, Gema, et al.
Publicado: (2020)

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
por: Dagher, Michael, et al.
Publicado: (2020)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis
por: Gatti, Milo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2t60mt1t6gv8e52j4los1cijj